Serum albumin and paraoxonase activity in Iranian veterans 20 years after sulfur mustard exposure

References

• Pourfarzam, S., Ghazanfari, T., Merasizadeh, J., Ghanei, M., Azimi, G., Araghizadeh, H., et al. Long-term pulmonary complications in sulfur mustard victims of Sardasht, Iran. Toxin Reviews 2009, 28, 8–13.
   Web of Science ®Google Scholar
• Ghanei, M., Mokhtari, M., Mohammad, M.M., Aslani, J. Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Eur J Radiol 2004, 52, 164–169.
   PubMed Web of Science ®Google Scholar
• Noort, D., Hulst, A.G., de Jong, L.P., Benschop, H.P. Alkylation of human serum albumin by sulfur mustard in vitro and in vivo: Mass spectrometric analysis of a cysteine adduct as a sensitive biomarker of exposure. Chem Res Toxicol 1999, 12, 715–721.
   PubMed Web of Science ®Google Scholar
• Kehe, K., Balszuweit, F., Steinritz, D., Thiermann, H. Molecular toxicology of sulfur mustard-induced cutaneous inflammation and blistering. Toxicology 2009, 263, 12–19.
   PubMed Web of Science ®Google Scholar
• Mallol, J., Aguirre, V., Espinosa, V. Increased oxidative stress in children with post infectious Bronchiolitis Obliterans. Allergol Immunopathol (Madr) 2011, 39, 253–258.
   PubMedGoogle Scholar
• Aviram, M., Kaplan, M., Rosenblat, M., Fuhrman, B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol 2005, 170, 263–300.
   PubMedGoogle Scholar
• Rozenberg, O., Rosenblat, M., Coleman, R., Shih, D.M., Aviram, M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: Studies in PON1-knockout mice. Free Radic Biol Med 2003, 34, 774–784.
   PubMed Web of Science ®Google Scholar
• Costa, L.G., Giordano, G., Furlong, C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochem Pharmacol 2011, 81, 337–344.
   PubMed Web of Science ®Google Scholar
• Allebrandt, K.V., Souza, R.L., Chautard-Freire-Maia, E.A. Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol Appl Pharmacol 2002, 180, 151–156.
   PubMed Web of Science ®Google Scholar
• Isik, B., Isik, R.S., Ceylan, A., Calik, O. Trace elements and oxidative stress in chronic obstructive pulmonary disease. Saudi Med J 2005, 26, 1882–1885.
   PubMed Web of Science ®Google Scholar
• Yildiz, A., Gur, M., Yilmaz, R., Demirbag, R., Polat, M., Selek, S., Celik, H., Erel, O. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008, 197, 257–263.
   PubMedGoogle Scholar
• Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M., Mackness, M. Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circulation 2003, 107, 2775–2779.
   PubMed Web of Science ®Google Scholar
• Maskara, S., Sen, N., Raj, J.P., Korah, I., Antonisamy, B. Correlation between lung injury score and serum albumin levels in patients at risk for developing acute lung injury. Nutrition 2000, 16, 91–94.
   PubMedGoogle Scholar
• Folsom, A.R., Ma, J., Eckfeldt, J.H., Nieto, F.J., Metcalf, P.A., Barnes, R.W. Low serum albumin. Association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol 1995, 5, 186–191.
   PubMedGoogle Scholar
• Tomás, M., Latorre, G., Sentí, M., Marrugat, J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 2004, 57, 557–569.
   PubMed Web of Science ®Google Scholar
• Aslan, M., Kosecik, M., Horoz, M., Selek, S., Celik, H., Erel, O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007, 191, 397–402.
   PubMed Web of Science ®Google Scholar
• Valiyaveettil, M., Alamneh, Y., Rezk, P., Biggemann, L., Perkins, M.W., Sciuto, A.M., Doctor, B.P., Nambiar, M.P. Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs. Biochem Pharmacol 2011, 81, 800–809.
   PubMed Web of Science ®Google Scholar
• Mackness, B., Durrington, P.N., Mackness, M.I. Low paraoxonase in Persian gulf war veterans self-reporting gulf war syndrome. Biochem Biophys Res Commun 2000, 276, 729–733.
   PubMed Web of Science ®Google Scholar
• Sepahvand, F., Shafiei, M., Ghaffari, S.M., Rahimi-Moghaddam, P., Mahmoudian, M. Paraoxonase phenotype distribution in a healthy Iranian population. Basic Clin Pharmacol Toxicol 2007, 101, 104–107.
   PubMed Web of Science ®Google Scholar
• Jafari, M., Ghanei, M. Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fluid antioxidant defense system in sulfur mustard-injured patients. Clin Toxicol (Phila) 2010, 48, 184–192.
   PubMed Web of Science ®Google Scholar
• Fallahi, F., Ghazanfari, T., Yaraee, R., Hassan, ZM., Foroutan, A., Soroush, MR., et al. Long-term cardiovascular symptoms and signs in mustard gas victims. Toxin Reviews 2009, 28, 30–33.
   Web of Science ®Google Scholar
• Can Demirdögen, B., Türkanoglu, A., Bek, S., Sanisoglu, Y., Demirkaya, S., Vural, O., Arinç, E., Adali, O. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin Biochem 2008, 41, 1–9.
   PubMed Web of Science ®Google Scholar
• Rajkovic, M.G., Rumora, L., Juretic, D., Grubisic, T.Z., Flegar-Mestric, Z., Vrkic, N., Sinjeri, Z., Barisic, K. Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis. Clin Biochem 2010, 43, 1375–1380.
   PubMed Web of Science ®Google Scholar
• Granér, M., James, R.W., Kahri, J., Nieminen, M.S., Syvänne, M., Taskinen, M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006, 47, 2429–2435.
   PubMed Web of Science ®Google Scholar
• Elkiran, E.T., Mar, N., Aygen, B., Gursu, F., Karaoglu, A., Koca, S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007, 7, 48.
   PubMed Web of Science ®Google Scholar
• Selek, S., Cosar, N., Kocyigit, A., Erel, O., Aksoy, N., Gencer, M., Gunak, F., Aslan, M. PON1 activity and total oxidant status in patients with active pulmonary tuberculosis. Clin Biochem 2008, 41, 140–144.
   PubMed Web of Science ®Google Scholar
• Novak, F., Vavrova, L., Kodydkova, J., Novak, F. Sr, Hynkova, M., Zak, A., Novakova, O. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med 2010, 10, 21–25.
   PubMedGoogle Scholar
• Selek, S., Aslan, M., Horoz, M., Gur, M., Erel, O. Oxidative status and serum PON1 activity in β-thalassemia minor. Clin Biochem 2007, 40, 287–291.
   PubMed Web of Science ®Google Scholar
• Aslan, M., Nazligul, Y., Horoz, M., Bolukbas, C., Bolukbas, F.F., Gur, M., Celik, H., Erel, O. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 2008, 196, 270–274.
   PubMed Web of Science ®Google Scholar
• Ferré, N., Marsillach, J., Camps, J., Mackness, B., Mackness, M., Riu, F., Coll, B., Tous, M., Joven, J. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006, 45, 51–59.
   PubMedGoogle Scholar
• Parra, S., Alonso-Villaverde, C., Coll, B., Ferré, N., Marsillach, J., Aragonès, G., Mackness, M., Mackness, B., Masana, L., Joven, J., Camps, J. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007, 194, 175–181.
   PubMedGoogle Scholar
• Costa, L.G., Vitalone, A., Cole, T.B., Furlong, C.E. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005, 69, 541–550.
   PubMed Web of Science ®Google Scholar
• Feingold, K.R., Memon, R.A., Moser, A.H., Grunfeld, C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998, 139, 307–315.
   PubMed Web of Science ®Google Scholar
• Navab, M., Hama-Levy, S., Van Lenten, B.J., Fonarow, G.C., Cardinez, C.J., Castellani, L.W., Brennan, M.L., Lusis, A.J., Fogelman, A.M., La Du, B.N. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997, 99, 2005–2019.
   PubMed Web of Science ®Google Scholar
• Kotur-Stevuljevic, J., Spasic, S., Jelic-Ivanovic, Z., Spasojevic-Kalimanovska, V., Stefanovic, A., Vujovic, A., Memon, L., Kalimanovska-Ostric, D. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem 2008, 41, 1067–1073.
   PubMed Web of Science ®Google Scholar
• Furlong, C.E., Cole, T.B., Jarvik, G.P., Costa, L.G. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 2002, 3, 341–348.
   PubMed Web of Science ®Google Scholar
• Singh, S., Verma, M., Nain, C.K., Leelamma, C.O., Goel, R.C. Paraoxonase (PON1) polymorphism & its relation with lipids in north west Indian Punjabis. Indian J Med Res 1999, 110, 133–137.
   PubMedGoogle Scholar
• Sumegová, K., Nagyová, Z., Waczulíková, I., Zitnanová, I., Duracková, Z. Activity of paraoxonase 1 and lipid profile in healthy children. Physiol Res 2007, 56, 351–357.
   PubMedGoogle Scholar
• Haley, R.W., Billecke, S., La Du, B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999, 157, 227–233.
   PubMed Web of Science ®Google Scholar
• Jarvik, G.P., Rozek, L.S., Brophy, V.H., Hatsukami, T.S., Richter, R.J., Schellenberg, G.D., Furlong, C.E. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000, 20, 2441–2447.
   PubMed Web of Science ®Google Scholar
• Tekes, S., Isik, B., Yildiz, T., Simsek, S., Isik, MR., Budak, T. Chronic obstructive pulmonary disease and paraoxonase-1 192 and 55 gene polymorphisms. Biotechnology & Biotechnological Equipment 2010, 24, 1644–1647.
   Web of Science ®Google Scholar
• Hernández, A.F., Gil, F., Leno, E., López, O., Rodrigo, L., Pla, A. Interaction between human serum esterases and environmental metal compounds. Neurotoxicology 2009, 30, 628–635.
   PubMed Web of Science ®Google Scholar
• Young, I.S., Woodside, J.V. Antioxidants in health and disease. J Clin Pathol 2001, 54, 176–186.
   PubMed Web of Science ®Google Scholar
• Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C.L., Newton, R.S., La Du, B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999, 26, 892–904.
   PubMed Web of Science ®Google Scholar
• Uthamalingam, S., Kandala, J., Daley, M., Patvardhan, E., Capodilupo, R., Moore, S.A., Januzzi, J.L. Jr. Serum albumin and mortality in acutely decompensated heart failure. Am Heart J 2010, 160, 1149–1155.
   PubMed Web of Science ®Google Scholar